National Fuel Gas (NFG) was initiated at Jefferies with a buy rating. Company offers a secure and growing dividend, significant leverage to LT Appalachian E&P and midstream opportunities, and potential for MLP formation, Jefferies said. Twelve-month price target is $79.

Penske (PAG) was upgraded at Sterne Agee to buy from neutral. Twelve-month price target is $52. Estimates were also increased, as the company has a lot of earnings momentum, Sterne Agee said.

Questar (STR) was initiated at Jefferies with a hold rating. Company offers exposure to the entire natural gas value chain, and stock offers a defensive equity play with high returns and attractive dividend growth, Jefferies said. Twelve-month price target is $24.

Southwest Gas (SWX) was initiated at Jefferies with a hold rating. Poised to benefit from ongoing regional economic and housing recoveries, Jefferies said. Twelve-month price target is $55.

Veeva (VEEV) was upgraded at Morgan Stanley to overweight. Twelve-month price target is $40. Market is underestimating the company's potential outside SFA, Morgan Stanley said.

Worthington (WOR) was upgraded at Keybanc to buy from hold. Twelve-month price target is $46. Stock has pulled back, but the long-term growth thesis remains intact, Keybanc said.

Stock Comments / EPS Changes

Crown Holding (CCK) 12-month price target was raised at Jefferies to $53. Driven by upside to company synergy targets, Jefferies said.

Green Plains (GPRE) 12-month price target, EPS estimates were raised at Jefferies. Driven by combination of strong ethanol margins and optimism of a favorable settlement of RFS debate, Jefferies said. Twelve-month price target is now $40. Buy rating.

Marvell Technology (MRVL) 12-month price target was increased at UBS to $17. Driven by increasing revenue momentum and second half from 3G and 4G TD-LTE SoCs, UBS said.

Maxim Integrated Products (MXIM) 12-month price target was increased at Jefferies to $39. Company is poised to see an order snapback from Samsung, and Samsung inventory has played out, Jefferies said.

Myriad Genetics (MYGN) 12-month price target was increased at Jefferies to $33. Driven by unexpected boost to BRCA pricing, Jefferies said.

Sally Beauty (SBH) numbers were cut at Sterne Agee. Twelve-month price target is now $32. Estimates were also reduced, given weather impacts, Sterne Agee said. Buy rating.

Follow TheStreet on Twitter and become a fan on Facebook

If you liked this article you might like

JPMorgan, U.S. Banks Face $3 Billion of Loan Losses From Catastrophic Hurricanes

14 Bank Stocks That Will Either Surge or Do Nothing

Mid-Cap Bank M&A Could Surge as GOP Looks to Overhaul Financial Regulations

Here's Why Mid-Sized Bank Stocks Could Get a Boost

Community Banks Could Be Big Winners in Treasury Regulation Overhaul